The Uromigos

Silke, Brian and Tom review exciting ESMO 2026 data in GU Oncology and more.

Danny Heng joins the show to discuss his ESMO 2026 presentation of LITESPARK-011 and the OS data. Published today in Annals of Oncology!

Martin Voss takes on the role of Host and interviews Brian and Tom about this phase 3 study of triplets in metastatic ccRCC. Published today in Annals of Oncology!

Chris Sweeney discusses this ANZUP trial which adds more phase 3 data to the high risk prostate cancer space.

Michiel Van Der Heijden joins us after his ESMO discussion and Tom's presentation to discuss how these critical data reshape the MIBC landscape.

Karim Fizazi joins Brian and Tom to discuss two ESMO 2026 presentations of long-term follow up data in mHSPC

Ben Garmezy discusses the phase 1 data of a novel mechanism in CRPC. This RIPTAC (Regulated Induced Proximity TargetingChimera) Molecule uses AR to enter the prostate cancer cell and inhibits BRD4 to interfere with cell transcription.

Jon Chatzkel joins us after his ESMO 2026 presentation to discuss ctDNA results from the KEYNOTE 905 trial.

Anders Ullen joins the show after his EMSO 2026 presentation looking at KN-905 for the period in which Cis-ineligible MIBC patients were randomized to immediate cystectomy vs neoadjuvant Pembro or EVP.

Rob Jones joins the show to discuss two phase 3 trials from ESMO 2026 which did not show benefit from chemotherapy + IO vs chemo in MIBC. We discuss the wider implications incorporating the NIAGARA data and in light of neo/adjuvant EVP.

Silke, Brian and Tom preview the major data to be presented at ESMO 2026

Shilpa Gupta joins us to discuss an X poll revealing equipoise about treatment approaches to resected high-risk upper tract urothelial cancer (UTUC).

Rob Dreicer joins the show to discuss the FDA approval of Lutetium Lu 177 in the mHSPC space and how to contextualize the benefit/risk

Toni Choueiri joins Brian and Tom to discuss a recent Nature paper regarding the novel HIF inhibitor, casdatifan, and biomarkers of response.

Ari Hakimi and Lyn Voung from MSKCC join Brian and Tom to discuss their recent Cancer Cell paper exploring the mechanistic impact of TKI-induced hypoxia on immune response in RCC.

Brian and Tom invite Neha Vapiwala, a Radiation Oncologist, to discuss areas of consensus and controversy from the PROTEUS trial of ADT +/- apalutamide in high-risk localized prostate cancer.

Travis Zack, CMO of Open Evidence, joins Brian and Tom to discuss the emergence of AI across the spectrum on cancer, drug development and application of data.

Bishoy Faltas joins Brian and Tom to discuss his IIT in bladder cancer. The intended discussion of the trials turned into an insightful discussion on the challenges and learning opportunities of IITs.

In our final episode recorded at APCCC, Louise Emmett joins us to discuss clinical results and mechanisms of PSMA upregulation by enzalutamide.

Tanya Dorff joins Tom and Brian to discuss her ASCO 2026 data on a novel dual targeting ADC in prostate cancer. The broader scope of ADC development in prostate cancer is discussed with a focus on cytopenia toxicity and future direcctions.